Skip to main content

Table 1 Transition probabilities in the model

From: Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany

Health state Transition to Monthly probability (%) Distribution for probabilistic analysis Source
Active TB
(MDR-TB; secondary MDR-TB and XDR-TB)
Sputum culture converted Variable Multivariate log-normal distribution [14]
Lost to follow-up 0.39 Beta [14]
Death MDR-TB, no cure: 2.21, MDR-TB, cured: 0.32
XDR-TB, no cure: 2.69% XDR-TB, cured: 0.39
Beta [21, 22]
Lost to follow-up Death 6.87 Beta [24]
Sputum culture converted Active secondary MDR-TB (relapse) 0.98 Beta [14]
MDR-TB or active XDR-TB (relapse) (21.4 to XDR-TB; 78.6 to MDR-TB) [14]
Treatment completion and cured Active secondary MDR-TB (reoccurrence) 0.20 Beta [21]
MDR-TB or active XDR-TB (reoccurrence) (21.4 to XDR-TB; 78.6 to MDR-TB) [14]
  1. MDR multidrug-resistant, TB tuberculosis, XDR extensively drug-resistant